^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CMB305
i
Other names: CMB305, ID-CMB305, LV305 + G305, LV305 plus G305, ID-G305/ID-LV305, G-305/LV-305, ID-LV305/ID-G305, LV-305/G-305, CMB-305, CMB 305, LV 305 plus G 305
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Merck (MSD)
Drug class:
Immunostimulant, NY ESO 1 inhibitor
Related drugs:
1year
NCI-2018-00926: Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (clinicaltrials.gov)
P1, N=15, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
Trial completion • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
|
cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305
over2years
NCI-2018-00926: Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (clinicaltrials.gov)
P1, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2021 --> Dec 2022
Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
|
Proleukin (aldesleukin) • CMB305 • ID-LV305
over3years
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. (PubMed, J Clin Oncol)
Although the combination of CMB305 and atezolizumab did not result in significant increases in PFS or OS compared with atezolizumab alone, some patients demonstrated evidence of an anti-NY-ESO-1 immune response and appeared to fare better by imaging than those without such an immune response. Combining prime-boost vaccines such as CMB305 with anti-programmed death ligand-1 therapies merits further evaluation in other clinical contexts.
Clinical • P2 data • Journal
|
CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • TLR4 (Toll Like Receptor 4)
|
CTAG1B expression
|
Tecentriq (atezolizumab) • CMB305
over3years
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (clinicaltrials.gov)
P1, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Dec 2021
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
|
Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous
Share via
